BCT.V - BriaCell Therapeutics Corp.

TSXV - TSXV Delayed Price. Currency in CAD
9.30
0.00 (0.00%)
At close: 9:44AM EDT
Stock chart is not supported by your current browser
Previous Close9.30
Open9.30
Bid9.45 x 0
Ask10.91 x 0
Day's Range9.30 - 9.30
52 Week Range0.04 - 33.00
Volume118
Avg. Volume739
Market Cap6.714M
Beta (5Y Monthly)2.54
PE Ratio (TTM)N/A
EPS (TTM)-10.14
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    BriaCell to Present Clinical Data at 2020 American Society of Clinical Oncology (ASCO) Annual Meeting May 29

    BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (BCT.V) (BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announces that it has been selected to present at the 2020 ASCO Annual Meeting, a virtual event held during the dates of the originally planned in-person Annual Meeting (May 29-June 2, 2020). The ASCO Annual Meeting represents the world’s largest gathering of oncology physicians, biotechnology executives, researchers, and investment analysts to discuss cutting-edge clinical research and therapeutics in oncology. Dr. Bill Williams, BriaCell’s President & CEO, and Dr. Charles Wiseman, BriaCell’s Scientific Founder and Director, will present clinical data and pathological findings from the Phase I/IIa studies of Bria-IMT™ alone or in combination with checkpoint inhibitors in advanced breast cancer patients.

  • GlobeNewswire

    BriaCell Continues Clinical Operations Amidst COVID-19 Pandemic

    Phase I/IIa clinical study of BriaCell’s lead candidate, Bria-IMT™, with Incyte Corporation’s immune checkpoint inhibitor, INCMGA00012, is ongoing and recruiting patients amidst the COVID-19 pandemic. Clinical and immune activity of Bria-IMT™, alone or in combination with checkpoint inhibitors,  KEYTRUDA® and INCMGA00012, in advanced breast cancer will be presented at the American Association for Cancer Research (AACR) Annual Meeting, postponed to August 2020. BERKELEY, Calif. and VANCOUVER, British Columbia, March 26, 2020 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (BCT.V) (BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announce that the Phase I/IIa clinical study of Bria-IMT™ with Incyte Corporation’s immune checkpoint inhibitor, INCMGA00012 is ongoing and recruiting patients amidst the COVID-19 pandemic.

  • GlobeNewswire

    BriaCell to Present Clinical and Immune Activity at AACR Annual Meeting

    Clinical and immune activity of BriaCell’s lead candidate, Bria-IMT™, alone or in combination with checkpoint inhibitors,  KEYTRUDA® and INCMGA00012, in advanced breast cancer will be presented at the American Association for Cancer Research (AACR) Annual Meeting on April 28, 2020. Clinical activity and potential correlation with immune activity and patient subsets will be presented. BERKELEY, Calif., and VANCOUVER, British Columbia, Feb. 26, 2020 (GLOBE NEWSWIRE) --  BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (BCT.V) (BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to announce that it has been selected to present at the American Association for Cancer Research (AACR) Annual Meeting, taking place on April 24–April 29, 2020 in San Diego, California.

  • GlobeNewswire

    BriaCell Announces Proposed Public Offering in the United States and Listing on NASDAQ

    BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (BCT.V) (BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to announce that it has commenced an underwritten public offering of its securities in the United States (the “Offering”). A registration statement relating to the securities subject to the Offering has been filed with the United States Securities and Exchange Commission (the "SEC") under the Securities Act of 1933, as amended (the “Securities Act”) but has not yet become effective. The Offering is subject to market and other conditions including the effectiveness of the registration statement, and there can be no assurance as to whether or when the Offering may be completed, or as to the actual size or terms of the offering.

  • GlobeNewswire

    BriaCell Announces Grant to Investigator Dr. Saveri Bhattacharya at Sidney Kimmel Cancer Center – Jefferson Health for Phase I/IIa Combination Study of Bria-IMT™

    Grant awarded to Dr. Saveri Bhattacharya, Principal Investigator of the Phase I/IIa combination study of Bria-IMT™ with KEYTRUDA® (by Merck) in advanced breast cancer at Thomas Jefferson University. Merck to provide KEYTRUDA® for use in the combination study.

  • GlobeNewswire

    BriaCell’s Clinical Data Accepted to be Presented at the Annual Symposium of Society of Surgical Oncology 2020 in Boston

    Safety and early efficacy data to be presented from clinical trial of Bria-IMT™ in combination with immune checkpoint inhibitors in advanced breast cancer:• Bria-IMT™ in.

  • GlobeNewswire

    BriaCell Invited to Present at Mount Sinai’s Frontiers in Academic Pathology Symposium at The New York Academy of Medicine

    BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (BCT.V) (BCTXD), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, announced today that it will present at the “Frontiers in Academic Pathology” symposium, hosted by the Icahn School of Medicine at Mount Sinai, to be held on Friday, January 31, 2020 at The New York Academy of Medicine, 1216 Fifth Avenue in New York. The symposium focus will include molecular biomarkers, experimental diagnostics and liquid biopsies, all of which factor heavily in the development of BriaCell’s companion diagnostics under development, including BriaCell’s HLA-matching hypothesis and recently-announced Grade I/II biomarkers.

  • Companies Like BriaCell Therapeutics (CVE:BCT) Can Be Considered Quite Risky
    Simply Wall St.

    Companies Like BriaCell Therapeutics (CVE:BCT) Can Be Considered Quite Risky

    We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

  • Baystreet

    Stocks in play: BriaCell Therapeutics Corp.

    Provided an update on the previously-announced top responder in the combination study of its lead candidate, ...

  • GlobeNewswire

    BriaCell Provides Update on Remarkable Responder

    BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (BCT.V) (BCTXD), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to provide an update on the previously-announced (Link) top responder (“Remarkable Responder”) in the combination study of its lead candidate, Bria-IMT™, with Incyte’s INCMGA00012, a PD-1 inhibitor. The patient, who had experienced notable tumor shrinkage while on treatment with Bria-IMT™ in combination with the PD-1 inhibitor pembrolizumab [KEYTRUDA®; manufactured by Merck & Co., Inc. (MRK)], has since transitioned to treatment in combination with INCMGA00012.

  • GlobeNewswire

    BriaCell Outlines New High Responding Patient Group ‘Biomarker’ Based on Cancer Grade

    BriaCell has identified a patient population Biomarker with high rate of clinical benefit from the treatments based on ‘Breast Cancer Grade’;Breast Cancer Grade correlates with.

  • GlobeNewswire

    BriaCell Completes Share Consolidation

    BERKELEY, Calif., and VANCOUVER, British Columbia, Jan. 02, 2020 -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXD), a clinical-stage.

  • GlobeNewswire

    BriaCell Therapeutics Corp. Announces Share Consolidation

    BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (BCT.V) (BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announces that its Board of Directors has approved a consolidation (the "Consolidation") of the Company's issued and outstanding common shares (the "Common Shares") on the basis of three hundred (300) pre-consolidation shares for one (1) post-consolidated share. The purpose of the Consolidation is to facilitate the Company’s ability to list on a recognized stock exchange in the United States of America.

  • GlobeNewswire

    BriaCell to Present at Biotech Showcase™ 2020 in San Francisco

    BERKELEY, Calif. and VANCOUVER, British Columbia, Dec. 17, 2019 -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage.

  • GlobeNewswire

    BriaCell Announces Clinical Data as Presented at the 2019 San Antonio Breast Cancer Symposium®

    Continued additive or synergistic activity observed in combination study of Bria-IMT™ with pembrolizumab (KEYTRUDA®; by Merck & Co., Inc.) as evident by tumor shrinkage even in the absence of “HLA Matching”. BERKELEY, Calif., and VANCOUVER, British Columbia, Dec. 13, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (BCT.V) (BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, is pleased to announce the presentation results of clinical studies with its lead product candidate,  Bria-IMT™,  summarized in two poster sessions during the 2019 San Antonio Breast Cancer Symposium® (SABCS). The December 12th poster summarized data of the Bria-IMT™ monotherapy study and the ongoing Phase I/IIa clinical study of Bria-IMT™ in combination with immune checkpoint inhibitors including pembrolizumab (KEYTRUDA®; manufactured by Merck & Co., Inc.), and more recently, Incyte’s INCMGA00012, in advanced breast cancer.

  • GlobeNewswire

    BriaCell to Present Clinical Findings at the 2019 San Antonio Breast Cancer Symposium® December 12th and 13th

    Safety and early efficacy data to be presented from clinical trial of Bria-IMT™ in combination with immune checkpoint inhibitors in advanced breast cancer: Bria-IMT™ in.

  • GlobeNewswire

    BriaCell Announces Voting Results of the Special Meeting of Shareholders

    BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (BCT.V) (BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today announced that the shareholders approved all matters addressed at the special meeting (the "Meeting") of the holders of common shares (the "Common Shares") in the capital of BriaCell held on October 22, 2019. At the Meeting, shareholders approved an ordinary resolution without variation providing the board of directors of the Company (the "Board") discretion to consolidate the Company's issued and outstanding Common Shares at a consolidation ratio of up to three-hundred (300) pre-consolidation Common Shares for one (1) post-consolidation Common Share (the "Consolidation") or such lower ratio as the Board may determine (the "Consolidation Resolution").

  • GlobeNewswire

    BriaCell Announces Closing of Non-Brokered Private Placement of $568,444

    BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (BCT.V) (BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announces that it has closed its previously-announced non-brokered private placement (the “Offering”) of common shares in the capital of the Company. Under the Offering, the Company issued a total of 8,120,633  common shares at a price of C$0.07 per common share for gross proceeds of C$568,444.

  • GlobeNewswire

    BriaCell Therapeutics Corp. to File Amendment to Management Information Circular

    BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (BCT.V) (BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announces that it has filed on SEDAR an amendment to its management information circular dated September 23, 2019 (the "Circular") to amend the maximum share consolidation ratio from 100:1 to 300:1 (the "Amendment"). BriaCell’s Board of Directors retains the discretion to fix the ratio and determine the timing for implementation of the share consolidation.  As indicated in the Circular, BriaCell is considering applying for listing on a recognized US stock exchange.  The conditions to any such listing would include the common shares trading at a minimum prescribed price and would, based on current trading values, require a significant share consolidation.

  • GlobeNewswire

    BriaCell Doses First Patient in Phase I/IIa Study Evaluating Bria-IMT™ in Combination with INCMGA00012 and Epacadostat in Patients with Advanced Breast Cancer

    Patient dosing has begun in the Phase I/IIa study evaluating the anti-tumor effects of BriaCell’s lead candidate, Bria-IMT™ in combination with Incyte’s INCMGA00012 and epacadostat in patients with advanced breast cancer. Cancer blocks the immune system preventing it from fighting and destroying cancer cells. Bria-IMT™ activates the immune system to fight and eliminate the cancer cells.

  • GlobeNewswire

    BriaCell Therapeutics Corp. to Clarify Record Date

    BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (BCT.V) (BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announced on August 23, 2019 that it will hold a special meeting of shareholders on October 22, 2019 (the "Meeting"). The Company would like to clarify that September 18, 2019 was the record date for determining shareholders of the Company entitled to receive notice of, and to vote at, the Meeting being held on October 22, 2019 in Toronto. The Company inadvertently advertised September 20, 2019 as the record date in its management information circular, dated September 23, 2019, for the upcoming Meeting.

  • GlobeNewswire

    Note from Chairman of BriaCell Therapeutics – October is Breast Cancer Awareness Month

    BERKELEY, Calif., and VANCOUVER, British Columbia, Oct. 01, 2019 -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF) is a clinical-stage.

  • GlobeNewswire

    BriaCell Appoints Immunology Expert, Dr. Cara L. Haymaker, to Scientific Advisory Board; BriaCell CEO to Lead Special ‘Targeted Immunotherapy’ Issue in Prestigious Journals

    BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (BCT.V) (BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today announced the addition of immunology expert, Cara L. Haymaker, Ph.D., to its Scientific Advisory Board, effective immediately. Additionally, Dr. Bill Williams, BriaCell’s President & CEO, has been selected to lead the upcoming special joint issue of the prestigious, peer-reviewed journals, Frontiers in Pharmacology and Frontiers in Oncology with the research topic of 'Targeted Immunotherapy for Cancer'. Dr. Cara Haymaker is an assistant professor at Department of Translational Molecular Pathology, Division of Pathology/Lab Medicine at The University of Texas MD Anderson Cancer Center.

  • GlobeNewswire

    BriaCell Announces Private Placement of up to $600,000

    BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (BCT.V) (BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to announce a non-brokered private placement (the “Private Placement”) of up to approximately 8,571,428 common shares in the capital of the Company for gross proceeds of up to approximately C$600,000 at a price per common share of C$0.07. The closing of the Offering is scheduled to occur on or about September 26, 2019.  All securities issued under the Private Placement will be subject to a hold period expiring 4 months plus 1 day following the closing date of the Private Placement.